English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background  Paracetamol/Orphenadrine is a fixed dose combination containing 35 mg orphenadrine and 450 mg paracetamol. It has analgesic and muscle relaxant properties and is widely available as generics. This study is conducted to investigate the relative bioavailability and bioequivalence between one fixed dose paracetamol/orphenadrine combination test preparation and one fixed dose paracetamol/orphenadrine combination reference preparation in healthy volunteers under fasted condition for marketing authorization in Malaysia.    Method  This is a single-center, single-dose, open-label, randomized, 2-treatment, 2-sequence and 2-period crossover study with a washout period of 7 days. Paracetamol/Orphenadrine tablets were administered after a 10-h fast. Blood samples for pharmacokinetic analysis were collected at scheduled time intervals prior to and up to 72 h after dosing. Blood samples were centrifuged, and separated plasma were kept frozen (− 15 °C to − 25 °C) until analysis. Plasma concentrations of orphenadrine and paracetamol were quantified using liquid-chromatography-tandem mass spectrometer using diphenhydramine as internal standard. The pharmacokinetic parameters AUC 0-∞ , AUC 0-t  and C max  were determined using plasma concentration time profile for both preparations. Bioequivalence was assessed according to the ASEAN guideline acceptance criteria for bioequivalence which is the 90% confidence intervals of AUC 0-∞ , AUC 0-t  and C max  ratio must be within the range of 80.00–125.00%.    Results  There were 28 healthy subjects enrolled, and 27 subjects completed this trial. There were no significant differences observed between the AUC 0-∞ , AUC 0-t  and C max  of both test and reference preparations in fasted condition. The 90% confidence intervals for the ratio of AUC 0-t  (100.92–111.27%), AUC 0-∞  (96.94–108.08%) and C max  (100.11–112.50%) for orphenadrine ( n  = 25); and AUC 0-t  (94.29–101.83%), AUC 0-∞  (94.77–101.68%) and C max  (87.12–101.20%) for paracetamol ( n  = 27) for test preparation over reference preparation were all within acceptable bioequivalence range of 80.00–125.00%.    Conclusion  The test preparation is bioequivalent to the reference preparation and can be used interchangeably.    Trial registration   NMRR- 17-1266-36,001 ; registered and approved on 12 September 2017.

bmc pharmacology and toxicology

A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition